Cefmetazole
Systematic (IUPAC) name | |
---|---|
(6R,7S)-7-(2-(cyanomethylthio)acetamido)-7-methoxy-3-((1-methyl-1H-tetrazol-5-ylthio)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid | |
Clinical data | |
AHFS/Drugs.com | International Drug Names |
MedlinePlus | a601206 |
Identifiers | |
CAS Number | 56796-20-4 |
ATC code | J01DC09 (WHO) |
PubChem | CID 42008 |
DrugBank | DB00274 |
ChemSpider | 38311 |
UNII | 3J962UJT8H |
KEGG | D00910 |
ChEBI | CHEBI:3489 |
ChEMBL | CHEMBL1201195 |
Chemical data | |
Formula | C15H17N7O5S3 |
Molar mass | 471.538 g/mol |
| |
| |
(what is this?) (verify) |
Cefmetazole is a cephamycin antibiotic, usually grouped with the second-generation cephalosporins.
Adverse effects
The chemical structure of cefmetazole, like that of several other cephalosporins, contains an N-methylthiotetrazole (NMTT or 1-MTT) side chain. As the antibiotic is broken down in the body, it releases free NMTT, which can cause hypoprothrombinemia (likely due to inhibition of the enzyme vitamin K epoxide reductase) and a reaction with ethanol similar to that produced by disulfiram (Antabuse®), due to inhibition of aldehyde dehydrogenase.[1]
Spectrum of bacterial susceptibility
Cefmetazole is a broad-spectrum cephalosporin antimicrobial and has been effective in treating bacteria responsible for causing urinary tract and skin infections. The following represents MIC susceptibility data for a few medically significant microorganisms.
- Bacteroides fragilis: 0.06 - >256 µg/ml
- Clostridium difficile: 8 - >128 µg/ml
- Staphylococcus aureus: 0.5 - 256 µg/ml (includes MRSA)
References
- ↑ Stork CM (2006). "Antibiotics, antifungals, and antivirals". In Nelson LH, Flomenbaum N, Goldfrank LR, Hoffman RL, Howland MD, Lewin NA (eds.). Goldfrank's toxicologic emergencies. New York: McGraw-Hill. p. 847. ISBN 0-07-143763-0. Retrieved 2009-07-03.
- ↑ http://www.toku-e.com/Assets/MIC/Cefmetazole%20free%20acid.pdf
|